MeiraGTx's innovative gene therapies for ocular diseases & more are backed by strong clinical data and funding. Click here to find out why MGTX stock is a Buy.

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Gene therapy specialist MeiraGTx ...

The venture aims to advance MeiraGTx’s Parkinson’s gene therapy through Phase III trials with up to $430m in funding from ...

With MeiraGTx eyeing up how to take the drug through phase 3 and onto commercialization, Hologen has stepped in. The ...

BofA analyst Alec Stranahan raised the firm’s price target on MeiraGTx (MGTX) to $14 from $12 and keeps a Buy rating on the shares, citing a ...

MeiraGTx has one gene therapy in a potentially pivotal clinical trial for cancer patients and another gene therapy ready to start Phase 3 in Parkinson’s disease. Completing the studies will be ...

MeiraGTx and Hologen form a neuro-AI drug development joint venture, with up to $430M in funding to advance Parkinson's and CNS treatments.

Today announced strategic collaboration with Hologen AI, including a $200 million upfront payment to MeiraGTx and the formation of a joint ...

Joint venture, Hologen Neuro AI, will expedite Phase 3 development of AAV-GAD for Parkinson’s Disease and industrialize ...

AnaptysBio, Inc. (ANAB) shares rallied 9.5% in the last trading session to close at $18.71. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

MeiraGTx Holdings plc ( NASDAQ:MGTX ) is possibly approaching a major achievement in its business, so we would like ...

LONDON and NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and ...